Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) (FAST)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00061633 |
Recruitment Status :
Completed
First Posted : June 2, 2003
Results First Posted : January 11, 2010
Last Update Posted : January 16, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Infections, Gram-Positive Bacterial Abscess Burns Cellulitis Ulcer Wound Infections | Drug: Telavancin Drug: Vancomycin or antistaphylococcal penicillin | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 169 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) |
Study Start Date : | June 2003 |
Actual Primary Completion Date : | January 2004 |
Actual Study Completion Date : | January 2004 |

Arm | Intervention/treatment |
---|---|
Experimental: Telavancin |
Drug: Telavancin
Telavancin 7.5 mg/kg/day IV (intravenously) for up to 14 days
Other Names:
|
Active Comparator: Standard of care for cSSSI
cSSSI - complicated skin and skin structure infections
|
Drug: Vancomycin or antistaphylococcal penicillin
Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days. |
- Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population [ Time Frame: 7-14 days following end of antibiotic treatment ]
- Cure: Resolution of clinically significant signs, symptoms associated with the skin infection present at study admission or improvement to the extent that the infectious process had been controlled and no further therapy with study medication was necessary.
- Failure: Inadequate response to study therapy or the need for significant surgical management (e.g. more than just routine debridement) of the infection site following antibiotic therapy and prior to the Test-of-Cure (TOC) visit.
- Indeterminate: Inability to determine outcome.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Patients must have a diagnosis of one of the following complicated skin and skin structure infections with either a suspected or confirmed Gram positive organism as the major cause of the infection:
- major abscess requiring surgical incision and drainage
- infected burn (see exclusion criteria for important qualifications)
- deep/extensive cellulitis
- infected ulcer (see exclusion criteria for important qualifications)
- wound infections
- Patients must be expected to require at least 4 days of intravenous antibiotic treatment
Exclusion Criteria:
- Previous systemic antibacterial therapy (with the exception of aztreonam and metronidazole) for > 24 hours within 7 days prior to the first dose of study medication unless the pathogen was resistant to prior treatment or the patient was a treatment failure (no clinical improvement after 3 days).
- Burns involving > 20% of body surface area or third degree/full thickness in nature, diabetic foot ulcers, ischemic ulcers/wounds, necrotizing fasciitis, gas gangrene, or mediastinitis.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00061633
United States, California | |
eStudy Site, 3450 Bonita Road, Ste 201 | |
Chula Vista, California, United States, 91910 |
Principal Investigator: | G. Ralph Corey, MD | Duke University |
Responsible Party: | Steven Barriere, Pharm.D., Vice President, Clinical and Medical Affairs, Theravance, Inc. |
ClinicalTrials.gov Identifier: | NCT00061633 |
Other Study ID Numbers: |
I6424-202a |
First Posted: | June 2, 2003 Key Record Dates |
Results First Posted: | January 11, 2010 |
Last Update Posted: | January 16, 2019 |
Last Verified: | January 2019 |
Infections Communicable Diseases Wound Infection Cellulitis Gram-Positive Bacterial Infections Disease Attributes Pathologic Processes Suppuration Inflammation |
Skin Diseases, Infectious Connective Tissue Diseases Bacterial Infections Bacterial Infections and Mycoses Vancomycin Penicillins Telavancin Anti-Bacterial Agents Anti-Infective Agents |